The B2 sample was randomly chosen out of a pool of six tumor samples (four ALL, one BL, one Burkitt’s-ALL) which could potentially harbor a BCR-ABL1, IGH/MYC, or CRLF2-P2RY8 rearrangement. Here, CRLF2 is linked to acute lymphoblastic leukemia.